Effects of sugammadex vs. pyridostigmine–glycopyrrolate on post‐operative nausea and vomiting: propensity score matching. Issue 1 (2nd October 2016)

• Record Type: Journal Article
• Authors: Lee, O. H.; Choi, G. J.; Kang, H.; Baek, C. W.; Jung, Y. H.; Woo, Y. C.; Oh, J.; Park, Y. H.
• Is Part Of: Acta anaesthesiologica scandinavica. Volume 61:Issue 1(2017:Jan.)
• Page Start: 39
• Page End: 45
• Publication Date: 2016-10-02
• Subjects: Anesthesiology -- Periodicals; Critical care medicine -- Periodicals; 617.9605
• DOI: 10.1111/aas.12813
• Languages: English
• ISSNs: 0001-5172

Abstract

Abstract : Background: Sugammadex is a new agent that reverses neuromuscular blockade by aminosteroid neuromuscular blocker. This retrospective study compared the effects of sugammadex on post‐operative nausea and vomiting (PONV) with those of a pyridostigmine–glycopyrrolate mixture. Methods: We reviewed the electronic medical records of 7179 patients who had received fentanyl‐based, intravenous, patient‐controlled analgesia (IV‐PCA) at Chung‐Ang University Hospital between January 1, 2010 and December 31, 2015. We categorized the patients into two groups on the basis of the type of reversal agent to neuromuscular blockade that was used: a traditional reversal agent (pyridostigmine–glycopyrrolate mixture; Group R; n = 7059) and sugammadex (Group S; n = 120). The propensity score matching method was then used to select 408 subjects in Group R and 115 subjects in Group S; on the basis of their covariates, these subjects were then matched with a counterpart in the other group. Results: After propensity score matching, the two groups were well balanced with respect to all baseline covariates. In Group S, the numeric rating scale of nausea on day 0, as well as the number of patients who vomited on day 0, was lower than that in group R. Furthermore, Group S used fewer rescue antiemetics on day 0 and had a higher complete response on day 0. Conclusion: Sugammadex might be more beneficial for PONV compared to pyridostigmine–glycopyrrolate mixture for patients who have received opioid‐based IV‐PCA.